TG Therapeutics Third Quarter Conference Call - TG THERAPEUTICS INC

Financial Performance:

• Global revenue for Q3 2026 reached approximately $260 million, up 61% year-over-year, comprising $233 million in U.S. net product revenue (up 52% YoY) and $19.9 million in license/milestone revenue.
• Consolidated gross margin stood at approximately 84%, with U.S. pre-MV gross margin maintaining a strong 87%.
• Operating income surged to $86 million for the quarter compared to $29 million in Q3 2025, driven by higher revenue and disciplined expense management.
• Net income was $55.5 million, or $0.35 per diluted share; Q3 2025 earnings included a substantial non-cash tax benefit which inflated prior period comparisons.
• Total operating expenses (R&D and SG&A excluding stock-based comp) were $107 million, down sequentially from $150 million in Q2 due to reduced manufacturing spend.
• Cash, cash equivalents, and investment securities totaled $557 million as of September 30.
• The company repurchased $100 million of common stock in Q3 (approx. 2 million shares at $49/share), with cumulative buybacks reaching $300 million (approx. 8.9 million shares).

Guidance and Future Outlook:

• Full-year 2026 global revenue guidance raised to $1 billion; U.S. pre-MV net product revenue guidance raised to $915–$920 million.
• Anticipates a strong Q4 2026, driving the U.S. Brionvi business to exceed a $1 billion annualized run rate for the first time.
• Full-year R&D and SG&A guidance (excluding stock-based comp) remains $450–$500 million.
• Simplified IV initiation regimen (single dose) targets potential regulatory approval and label update around mid-2027.
• Subcutaneous (SubQ) Brionvi Phase 3 top-line results expected year-end 2026 or early 2027, with a potential commercial launch targeted for 2028.
• Management expects the SubQ launch to more than double peak sales opportunity by capturing the self-administration market segment.

Business Segments and Product Lines:

• Brionvi (IV): Treatment-naive patients now represent ~40% of new starts (up from ~25% at launch); strong growth in patients aged 18–40; hospital business showing record momentum in September/October.
• Brionvi (Lifecycle Innovation): The "Enhance" study met its primary endpoint for bioequivalence with a consolidated single-dose initiation regimen, reducing infusion-related reactions (16% vs. 26%) and simplifying administration.
• Brionvi (SubQ): Phase 1 data supports quarterly 400mg dosing with ~62% bioavailability; PK modeling suggests superior exposure relative to IV; designed as an auto-injector pen-like device for 2028 launch.
• Azara Cell (CAR-T): First-in-human data for allogeneic CD19 CAR-T in progressive MS showed 90% of evaluable patients had stable or improved EDSS scores at day 90; no grade 3+ CRS or ICANS observed; significant unmet need addressed with B-cell depletion in the CNS.
• Pipeline Expansion: Phase 2 studies active in generalized myasthenia gravis (sequencing FCRN inhibition + Brionvi) and treatment-resistant schizophrenia (B-cell depletion hypothesis).

Market and Competitive Landscape:

• Brionvi positioning as the most prescribed anti-CD20 therapy among new starts; real-world evidence (ENABLE) and long-term data (Ultimate) reinforce differentiation versus competitors.
• Recent indirect comparison suggests Brionvi (Obinutuzumab) carries a 44% lower risk of disability progression vs. Ocrelizumab and 49% lower vs. Ocrelizumab (Opzelura).
• BTK inhibitors viewed as primarily competing in the genericized oral space rather than the high-efficacy CD20 segment; efficacy and dosing frequency (twice daily) cited as limitations compared to CD20s.
• Market shifting toward initial high-efficacy therapy choice; Brionvi gaining share from patients switching from other CD20 therapies.
• Significant competitive gap identified in the self-administration segment (currently ~35% of new anti-CD20 starts), where Brionvi SubQ aims to dominate.

Risks and Challenges:

• Forward-looking statements regarding future financial performance, clinical outcomes, and regulatory approvals are subject to risks detailed in SEC filings.
• Gross-to-net pressures from payer contracting, government discounts, and mix changes remain a long-term focus, though management maintains confidence in pricing power and sustainability.
• 340B policy changes may impact Medicare patients at 340B hospitals (approx. 5% of business), though expected to have minimal overall financial impact.
• Regulatory approval timelines for the simplified IV initiation and SubQ formulations (mid-2027 and 2028) carry execution risk.
• CAR-T therapy (Azara Cell) involves early-stage clinical risk in a high-complexity population (progressive MS).

Management Commentary and Tone:

• Tone is highly confident and celebratory, citing a "remarkable" achievement of reaching $1 billion annualized revenue in less than four years.
• Management emphasizes "disciplined capital allocation," balancing heavy investment in pipeline (SubQ, CAR-T) with shareholder returns (buybacks).
• CEO Mike Weiss describes the $1 billion milestone as a "starting line," asserting the company is still early in its value creation journey.
• Strong emphasis on the synergy between established commercial infrastructure (Brionvi IV) and new product launches (SubQ, CAR-T) to create a "value creation engine."

Analyst Questions and Answers:

• Gross-to-Net & Competition: Management dismissed concerns about unsustainable aggressive contracting, noting pricing increases offset discounts; confirmed physicians choose Brionvi based on clinical profile.
• BTK Inhibitors: Confirmed BTK class (e.g., Remibrutinib) lacks efficacy/safety to compete directly with high-efficacy CD20s; likely to remain in the oral/generic space.
• Exit Rate: Confirmed new patient acquisition exceeds attrition, with no specific numbers disclosed but "persistence remains high."
• SubQ Launch Details: Confirmed launch with an auto-injector in 2028; CMC readiness is on track; feedback indicates preference for pen-like auto-injector over Roche's on-body injector.
• Simplified IV Dosing: No pricing change expected for the consolidated dose; impact expected to materialize in late H2 2027 post-approval.
• 340B Exposure: Minimal impact expected as the vast majority of revenue is commercial; potential positive scenarios identified based on hospital pricing dynamics.
• SubQ Uptake: Expects faster uptake than IV Brionvi due to established brand awareness and existing commercial infrastructure.

Other Key Points:

• Seven-year data from the Ultimate program showed an annualized relapse rate of 0.018 and 88% of patients remaining free of 24-week confirmed disability progression.
• Switching data indicates ~70% of patients transitioning from Ocrelizumab to Brionvi do not experience "wearing-off" symptoms compared to 60% on Ocrelizumab.
• Hospital business metrics hit record highs in September and October, driven by sustained educational efforts and growing clinical confidence.
• The company views the SubQ formulation as additive to the IV business, aiming to make Brionvi a preferred option regardless of administration preference.